摘要
目的 :研究川芎嗪对人肝癌多药耐药细胞系HepG2 /ADM多药耐药性的逆转效应及对P gp170表达的影响 ,深入探讨川芎嗪逆转肿瘤细胞多药耐药的机理。方法 :应用细胞培养、细胞毒实验、RT PCR、流式细胞仪等方法 ,观察川芎嗪对体外培养HepG2 /ADM细胞的逆转作用。结果 :川芎嗪可以使细胞膜表面的P gp170表达减弱 ,增加阿霉素对HepG2 /ADM细胞的毒性 ;RT PCR结果表明川芎嗪可以使HepG2 /ADM细胞的mdr1基因表达减弱 ;流式细胞仪检测结果表明川芎嗪可以使HepG2 /ADM细胞内罗丹明 12 3的浓度增加 ,从而增加阿霉素对HepG2 /ADM细胞的毒性。结论 :川芎嗪具有在体外逆转HepG2 /ADM细胞多药耐药的效应 ,具有临床应用前景。
Objective: To study the reverse effec t of ligustrazine (TMP) on HepG2/ADM, a herd of hepatocellular carcinoma cell, mult idurg resistance(MDR) and the influence of P-gp170 expression. Meth od: The reverse effect of ligustrazine on HepG2/ADM cell was observe d, with the methods of cell culture,MTT′s analyze,RT-PCR and Flow cytometri c, etc. Result: Ligustrazine could make MDR of cell lin e of HepG2/ADM reduce the expression of P-gp170, enhance the density of adriam ycin in cell and increase the adriamycin′s cytotoxicity. With the Flow cytome tric, the results of RT-PCR showed the transcriptional activity of the MDR1 de creased. Conclusion:Ligustrazine can reverse MDR of HCC cell line of HepG2/ADM and has prospect in clinical use. [
出处
《中国中药杂志》
CAS
CSCD
北大核心
2004年第10期970-973,共4页
China Journal of Chinese Materia Medica
基金
重庆市卫生局中医药课题 (渝中医〔2 0 0 2〕 3 9)
